OR WAIT null SECS
Growth and Advancements in Fill/Finish
Employing novel technologies and more patient-centric approaches
Delving into Biopharmaceutical Development and Manufacturing
Quality Considerations in Changing Excipient Providers
May 04, 2022
Accelerate Diagnostics’ new blood culture kit demonstrated 94% or greater accuracy on positive blood cultures relative to matrix-assisted laser desorption/ionization (MALDI).
May 03, 2022
FDA’s Office of Compliance has released its 2021 Annual Report, which highlights the agency’s successes in public health.
FDA has issued the final guidance on electronic postmarketing safety reports in a series of guidance documents.
VYDURA has been granted marketing authorization by the European Commission for both acute treatment of migraine and prophylaxis of episodic migraine.
Resolving operational bottlenecks makes mAb manufacturing more efficient.
Researchers demonstrated a new cell lysis method using a novel solution to improve viral vector production.
Inhalation formulations are complex, and empirical data are essential for realizing optimal solutions.
Advances in therapeutic modalities and an increase in molecular complexity have led to the need for an evolution in drug delivery approaches over the years.
Ongoing advances in technology and modeling techniques are helping to align all the objectives of both drug manufacturers and patients.
Using more exacting analytical tools can give a clearer assessment of gene-editing outcomes.